文献速递病毒性肝炎

新型HBx突变F30V与肝细胞癌相关并降低HBV复制效率、增强HBx抗凋亡活性

The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro.
PubMed 文献 · Clin Microbiol Infect · 2018-11-23

该研究在123例慢性HBV感染者中分析HBx基因变异与肝细胞癌(HCC)的关联,发现F30V是唯一与HCC相关的HBx突变(HCC组18.5% vs 非HCC组1.0%,p=0.002)。体外实验显示F30V使pgRNA和核心相关HBV-DNA分别降低40%和60%,减少HBx与cccDNA结合并降低HBx稳定性,同时减少凋亡细胞比例并增加HBx-Ser-31被PI3K-Akt磷酸化的概率。

要点

  • F30V是唯一与HBV相关HCC独立相关的HBx突变。
  • F30V降低HBV复制效率并减少HBx与cccDNA结合。
  • F30V增强HBx抗凋亡活性,可能促进肝细胞存活。

核心结论

  • F30V在体内与HBV诱导的HCC密切相关,体外通过影响HBx与cccDNA结合降低HBV复制效率并增强HBx抗凋亡活性。
  • F30V虽削弱HBV复制能力,但可能促进肝细胞存活,从而潜在允许病毒持续产生后代并启动HBV驱动的肝癌发生。

研究设计与样本

  • 研究纳入123例慢性HBV感染者,其中27例HCC(77.9%基因型D,22.1%基因型A),96例无HCC(75%基因型D,25.0%基因型A)。
  • 体外使用野生型或突变型线性HBV基因组转染HepG2细胞,评估pgRNA和核心相关HBV-DNA水平、HBx与cccDNA结合及凋亡和细胞周期。

主要发现

  • F30V在HCC患者中占18.5%(5/27),在非HCC患者中占1.0%(1/96),p=0.002,多因素分析证实其与HCC相关。
  • 体外F30V使pgRNA和核心相关HBV-DNA较野生型分别降低40%和60%(p<0.05),并显著减少HBx与cccDNA结合、降低HBx稳定性。
  • F30V使凋亡细胞比例降低(14.8±6.8% vs 19.1±10.1%,p<0.01),不影响细胞周期进程,并增加HBx-Ser-31被PI3K-Akt激酶磷酸化的概率。

临床怎么用

  • 检测HBx F30V等与HCC相关的病毒遗传标志物有助于识别HCC高风险患者,从而加强肝脏监测和/或早期抗HBV治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We aimed to investigate HBx genetic elements correlated with hepatitis B virus (HBV) -related hepatocellular carcinoma (HCC) and their impact on (a) HBV replicative efficiency, (b) HBx binding to circular covalently closed DNA (cccDNA), (c) apoptosis and cell-cycle progression, and (d) HBx structural stability. METHODS: This study included 123 individuals chronically infected with HBV: 27 with HCC (77.9% (21/27) genotype D; 22.1% (6/27) genotype A) and 96 without HCC (75% (72/96) genotype D; 25.0% (24/96) genotype A). HepG2 cells were transfected by wild-type or mutated linear HBV genome to assess pre-genomic RNA (pgRNA) and core-associated HBV-DNA levels, HBx-binding onto cccDNA by chromatin immunoprecipitation-based quantitative assay, and rate of apoptosis and cell-cycle progression by cytofluorimetry. RESULTS: F30V was the only HBx mutation correlated with HCC (18.5% (5/27) in HCC patients versus 1.0% (1/96) in non-HCC patients, p 0.002); a result confirmed by multivariate analysis. In vitro, F30V determined a 40% and 60% reduction in pgRNA and core-associated HBV-DNA compared with wild-type (p <0.05), in parallel with a significant decrease of HBx binding to cccDNA and decreased HBx stability. F30V also decreased the percentage of apoptotic cells compared with wild-type (14.8 ± 6.8% versus 19.1 ± 10.1%, p <0.01, without affecting cell-cycle progression) and increased the probability of HBx-Ser-31 being phosphorylated by PI3K-Akt kinase (known to promote anti-apoptotic activity). CONCLUSIONS: F30V was closely correlated with HBV-induced HCC in vivo, reduced HBV replicative efficiency by affecting HBx-binding to cccDNA and increased anti-apoptotic HBx activity in vitro. This suggests that F30V (although hampering HBV's replicative capacity) may promote hepatocyte survival, so potentially allowing persistent production of viral progeny and initiating HBV-driven hepatocarcinogenesis. Investigation of viral genetic markers associated with HCC is crucial to identify those patients at higher risk of HCC, who hence deserve intensive liver monitoring and/or early anti-HBV therapy.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Salpini R, Surdo M, Cortese MF, et al. The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro. Clin Microbiol Infect. 2018. PMID: 30472417. doi:10.1016/j.cmi.2018.11.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。